● Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Condition: Breast Cancer · Sponsor: AstraZeneca

PhasePhase 3

Planned participants625

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

AstraZeneca Breast Cancer Study Locator Service · +1-877-400-4656 · az-bcsl@careboxhealth.com

Always discuss trial participation with your own doctor first.

Locations (321)

Research Site	Daphne, Alabama, United States	Recruiting
Research Site	Springdale, Arkansas, United States	Recruiting
Research Site	Duarte, California, United States	Withdrawn
Research Site	Fountain Valley, California, United States	Not Yet Recruiting
Research Site	Glendale, California, United States	Recruiting
Research Site	Sacramento, California, United States	Recruiting
Research Site	Santa Rosa, California, United States	Withdrawn
Research Site	Aurora, Colorado, United States	Recruiting
Research Site	Denver, Colorado, United States	Not Yet Recruiting
Research Site	New Haven, Connecticut, United States	Recruiting
Research Site	Altamonte Springs, Florida, United States	Not Yet Recruiting
Research Site	Jacksonville, Florida, United States	Withdrawn

+ 309 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06103864